Dorte Stavnem

Dorte Stavnem

Auto-generated profile, based on publicly available information

Dorte Stavnem

The Department of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet , Blegdamsvej 9, 2100 Copenhagen

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2026 in EP Europace
Verified
Journal Article
Open access
DSDorte Stavnem
Dorte Stavnem
PBPriya Bhardwaj
Priya Bhardwaj
RJReza Jabbari
Reza Jabbari
TEThomas Engstrøm
Thomas Engstrøm
LBLia Evi Bang
Lia Evi Bang
BWBo Gregers Winkel
Bo Gregers Winkel
Coronary artery spasm can be life-threatening. Clinically significant complications include myocardial infarction, ventricular arrhythmias, and sudden cardiac arrest. Although challenging to diagnose, new international guidelines have been published to guide the diagnosis of coronary artery spasm when this is the suspected cause of cardiac arrest. The aim of this review is to consider existing knowledge for the diagnosis and management of coronary artery spasm in survivors of sudden cardiac arrest. Twenty-seven original research articles (written in English) involving a total of 1541 survivors of sudden cardiac arrest associated with coronary artery spasm form the basis of this review. Most cohorts included >75% male participants with a mean age range of 45–63 years. A positive family history or coronary risk factors of coronary artery disease are not commonly found, albeit many survivors are smokers (ranged 17–100% across cohorts). Provocative testing for coronary spasm was reported in 25 of the evaluated papers, but the indications for testing were inconsistently specified. A high recurrence rate (up to 45%) of life-threatening ventricular arrhythmias was reported, and implantable cardioverter-defibrillator placement varied markedly. In conclusion, diagnosing coronary artery spasm as a cause of sudden cardiac arrest is challenging. The pathophysiological understanding is limited. Knowledge gaps include the incidence and prevalence, as well as the usefulness of provocative testing in survivors. More data are needed regarding patient risk stratification, indications for implantable cardioverter-defibrillator insertion, and optimal pharmacological therapy.

31 January 2026 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
DSDorte Stavnem
Dorte Stavnem
PBPriya Bhardwaj
Priya Bhardwaj
JTJacob Tfelt-Hansen
Jacob Tfelt-Hansen
CHCarl Johann Hansen
Carl Johann Hansen
BWBo Gregers Winkel
Bo Gregers Winkel
Background: Andersen–Tawil syndrome is characterized by a symptom triad of cardiac electrical abnormalities, periodic muscular paralysis, and distinct dysmorphic manifestations. A history of unexplained syncope has been associated with a more serious phenotype with increased risk of life-threatening arrhythmia. Due to the syndrome’s rarity and highly variable clinical presentation, diagnosis remains challenging. Case summary: This report highlights the importance of comprehensive diagnostic workup following a sudden cardiac arrest, particularly emphasizing the value of genetic testing. We present a 61-year-old male hypertensive patient who initially presented with a first-time syncopal episode. Initial investigations revealed ventricular ectopy exceeding 12 000 premature ventricular contractions, occasional QT prolongation of >500 ms, and mildly reduced left ventricular ejection fraction (50%). Outpatient diagnostic investigations did not yield a diagnosis. While awaiting ablation, the patient suffered from an out-of-hospital cardiac arrest and was successfully resuscitated after 17 min. Complete diagnostic work-up including guideline-adherent assessments and genetic testing eventually revealed Andersen–Tawil syndrome. The subsequent family evaluations supported the diagnosis. Discussion: Diagnosis was unexpected as the patient presented with isolated cardiac manifestations and a late onset of symptoms. Cardiomyopathy and primary arrhythmic disorders were relevant differential diagnoses and investigated during admission. No clinical assessment is pathognomonic for Andersen–Tawil syndrome, making genetic testing essential for establishing a definitive diagnosis. While historically characterized as a long QT variant, research suggests Andersen–Tawil syndrome is its own disease entity. Pharmacological management follows established channelopathy principles, though the protective efficacy of beta-blockers and flecainide remains uncertain in this syndrome.

18 October 2021 in Cardiology
Verified
Journal Article
Closed access
PDF file
DSDorte Marie Stavnem
Dorte Marie Stavnem
RHRakin Hadad
Rakin Hadad
BLBjørn Strøier Larsen
Bjørn Strøier Larsen
ONOlav Wendelboe Nielsen
Olav Wendelboe Nielsen
MFMark Aplin Frederiksen
Mark Aplin Frederiksen
ASAhmad Sajadieh
Ahmad Sajadieh
Background: In patients with atrial fibrillation (AF), the long-term prognosis of long electrocardiographic pauses in the ventricular action is not well studied. Methods: Consecutive Holter recordings in patients with AF (n = 200) between 2009 and 2011 were evaluated, focusing on pauses of at least 2.5 s. Outcomes of interest were all-cause mortality and pacemaker implantation. Results: Forty-three patients (21.5%) had pauses with a mean of 3.2 s and an SD of 0.9 s. After a median follow-up of 99 months (ranging 89–111), 47% (20/43) of the patients with and 45% (70/157) without pauses were deceased. Pauses of ≥2.5 s did not constitute a risk of increased mortality: HR = 0.75 (95% CI: 0.34–1.66); p = 0.48, neither did pauses of ≥3.0 s: HR = 0.43 (95% CI: 0.06–3.20); p = 0.41. Sixteen percent of patients with pauses underwent pacemaker implantation during follow-up. Only pauses in patients referred to Holter due to syncope and/or dizzy spells were associated with an increased risk of pacemaker treatment: HR = 4.7 (95% CI: 1.4–15.9), p = 0.014, adjusted for age, sex, and rate-limiting medication. Conclusion: In patients with AF, prolonged electrocardiographic pauses of ≥2.5 s or ≥3.0 s are not a marker for increased mortality in this real-life clinical study.